Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors

Autor: Yoshikazu Takahashi, Akira Okita, Keigo Komine, Masahiro Takahashi, Kota Ouchi, Sonoko Chikamatsu, Yoshinari Okada, Sadayuki Kawai, Yuki Kasahara, Hidekazu Shirota, Chikashi Ishioka, Hiroo Imai, Ken Saijo, Masanobu Takahashi, Shin Takahashi, Makio Gamoh, Shukuei Ito
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Adult
Male
medicine.medical_specialty
Multivariate analysis
medicine.medical_treatment
Thrombomodulin
030204 cardiovascular system & hematology
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Surgical oncology
Internal medicine
hemic and lymphatic diseases
Neoplasms
Solid tumors
medicine
Blood test
Humans
Aged
Retrospective Studies
Disseminated intravascular coagulation
Aged
80 and over
Chemotherapy
Fibrin degradation product
medicine.diagnostic_test
business.industry
Standard treatment
Cancer
Hematology
General Medicine
Recombinant human soluble thrombomodulin
Syndrome
Disseminated Intravascular Coagulation
Middle Aged
medicine.disease
Recombinant Proteins
Survival Rate
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Surgery
Original Article
Female
business
circulatory and respiratory physiology
Zdroj: International Journal of Clinical Oncology
ISSN: 1437-7772
1341-9625
Popis: Background Recombinant human soluble thrombomodulin (rTM) has been established and introduced in the clinic as a standard treatment for disseminated intravascular coagulation (DIC). However, the efficacy and safety of rTM for DIC associated with solid tumors (DIC-STs) have not been fully established. Here, we performed a retrospective analysis of the clinical outcomes of rTM for DIC-STs and considered a treatment strategy with rTM for DIC-STs. Methods Patients with DIC-STs between November 2009 and March 2016 in 2 cancer core hospitals were retrospectively analyzed. Data, including patient background, treatment course, and clinical outcomes of rTM for DIC-STs, were extracted. The clinical outcomes were evaluated by comparing the DIC score, resolution rate, and overall survival (OS) duration. Results The study included 123 patients with DIC-STs. The median OS in all patients was 41 days. The DIC resolution rate was 35.2%. DIC scores and DIC-related blood test data (fibrin degradation product and prothrombin time-international normalized ratio) significantly improved at the end of rTM administration (P
Databáze: OpenAIRE
Externí odkaz: